Device Week, 28 August 2020 – Medtronic Goes After Competition; Freenome Attacks Colorectal Cancer

This week’s podcast includes discussion of Medtronic’s latest sales and earnings report and an update on Freenome’s multiomics liquid biopsy test for early-stage colorectal cancer. Listen to the podcast via the player below: Medtech Insight articles addressing topics discussed in this episode: Medtronic ‘Plays Offense’ Despite Pandemic Challenges, Q1 Results Provide Optimism https://bit.ly/3b2c1iB ADA 2020: Medtronic Explains Strategy To Return Growth To Diabetes Business https://bit.ly/3dkyCX4 Freenome Raises $270M In Series C, Accelerates Trial For Colorectal Cancer Test https://bit.ly/32xADfd Freenome Scores $160M In New Funding. So What's Next? https://bit.ly/32zzKCK